In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 151 to 200 of 412

Sort by

Type: GuidanceRemove Type: Guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]	Highly specialised technology	29 January 2025
Fruquintinib for previously treated metastatic colorectal cancer ID6274	Technology appraisal guidance	5 March 2025
Gambling-related harms: identification, assessment and management	NICE guideline	TBC
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]	Technology appraisal guidance	TBC
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]	Technology appraisal guidance	25 June 2025
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain	Medical technologies guidance	TBC
Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]	Technology appraisal guidance	TBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]	Technology appraisal guidance	TBC
Glaucoma - lerdelimumab (CAT-152) [ID383]	Technology appraisal guidance	TBC
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202]	Technology appraisal guidance	TBC
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238	Technology appraisal guidance	TBC
Guselkumab for treating moderately to severely active ulcerative colitis ID6237	Technology appraisal guidance	TBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]	Technology appraisal guidance	TBC
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]	Technology appraisal guidance	30 April 2025
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]	Technology appraisal guidance	TBC
Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251]	Technology appraisal guidance	TBC
Ibrutinib for untreated mantle cell lymphoma [ID1221]	Technology appraisal guidance	TBC
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]	Technology appraisal guidance	23 April 2025
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]	Technology appraisal guidance	TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]	Technology appraisal guidance	TBC
Implanting a baroreceptor stimulation device for resistant hypertension	Interventional procedures guidance	TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]	Technology appraisal guidance	TBC
Insertion of neo-chordae into the beating heart for mitral regurgitation	Interventional procedures guidance	TBC
Insulin icodec for treating type 2 diabetes [ID6175]	Technology appraisal guidance	TBC
Intermittent urethral catheters for urinary management in adults : Late Stage Assessment	Health technology evaluation	TBC
Intrapartum Care - maternal hyponatremia	NICE guideline	TBC
Intrapartum care - uterotonics for postpartum haemorrhage	NICE guideline	3 December 2024
Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention	Interventional procedures guidance	5 February 2025
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]	Technology appraisal guidance	TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]	Technology appraisal guidance	TBC
Iptacopan for treating complement 3 glomerulopathy ID6283	Technology appraisal guidance	TBC
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981	Technology appraisal guidance	18 June 2025
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]	Technology appraisal guidance	TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]	Technology appraisal guidance	TBC
Kidney Cancer	NICE guideline	TBC
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]	Technology appraisal guidance	TBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]	Technology appraisal guidance	TBC
Laparoscopic insertion of a non-active implant for gastro-oesophageal reflux disease	Interventional procedures guidance	17 April 2025
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]	Technology appraisal guidance	5 February 2025
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]	Technology appraisal guidance	TBC
Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]	Highly specialised technology	5 March 2025
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]	Technology appraisal guidance	TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]	Technology appraisal guidance	TBC
Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166]	Technology appraisal guidance	TBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]	Technology appraisal guidance	TBC
Lifileucel for previously treated unresectable or metastatic melanoma ID3863	Technology appraisal guidance	TBC
Linzagolix for treating symptoms of endometriosis [ID6357]	Technology appraisal guidance	25 June 2025
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]	Technology appraisal guidance	TBC
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphomas after first-line chemotherapy when a stem cell transplant is suitable [ID3887]	Technology appraisal guidance	11 December 2024
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]	Technology appraisal guidance	TBC

Results per page

10
25
50
All